Article

Development of tau aggregation inhibitors for Alzheimer's disease.

Max-Planck-Institute for Molecular Physiology, Dortmund, Germany.
Angewandte Chemie International Edition (Impact Factor: 11.34). 03/2009; 48(10):1740-52. DOI: 10.1002/anie.200802621
Source: PubMed

ABSTRACT A variety of human diseases are suspected to be directly linked to protein misfolding. Highly organized protein aggregates, called amyloid fibrils, and aggregation intermediates are observed; these are considered to be mediators of cellular toxicity and thus attract a great deal of attention from investigators. Neurodegenerative pathologies such as Alzheimer's disease account for a major part of these protein misfolding diseases. The last decade has witnessed a renaissance of interest in inhibitors of tau aggregation as potential disease-modifying drugs for Alzheimer's disease and other "tauopathies". The recent report of a phase II clinical trial with the tau aggregation inhibitor MTC could hold promise for the validation of the concept. This Review summarizes the available data concerning small-molecule inhibitors of tau aggregation from a medicinal chemistry point of view.

0 Bookmarks
 · 
181 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neurofibrillary tangles composed of tau protein and senile plaque accumulated by amyloid-β (Aβ) are two hallmarks in Alzheimer disease (AD). In the patients with AD, tau is abnormally hyperphosphorylated, mutated or misfolding, which endows tau with stronger tendency to aggregate. Tau protein has the potency to mediate neuron toxicity of Aβ. The reduction of tau level ameliorates degeneration of neuron axon. Therefore, many researches are exploring new methods to regulate tau level. This review will mainly focus on small molecules that can directly inhibit tau fibrillation or control tau accumulation by regulating tau phosphorylation process.
    Chinese Journal of Chemistry 10/2014; · 0.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A direct method for the synthesis of N-substituted-5-arylidene-rhodanines has been reported in high yield via [bmim]OAc-catalyzed one-pot four-component domino Knoevenagel condensation of primary amine, carbon disulfide, ethyl chloroacetate, and aromatic aldehyde under neat condition. The catalytic role of [bmim]OAc is due to the acidic nature of C-2 hydrogen of bmim cation and the basic nature of acetate anion in the noncovalent interactions. The synthetic methodology is simple and offers a wide scope for the synthesis of N-substituted-5-arylidene-rhodanines.
    Journal of Heterocyclic Chemistry 08/2014; 51(S1):E129-E139. · 0.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Myricetin is a natural flavonol found in many grapes, berries, fruits, vegetables, herbs as well as other plants. Recent studies have identified potential anti-amyloidogenic activity for this compound. In this study, the kinetics of amyloid fibril formation by hen egg white lysozyme (HEWL) and the anti-fibril forming activity of myricetin were investigated. We demonstrate that myricetin significantly inhibits the fibrillation of HEWL and the inhibitory effect is dose-dependent. Interestingly, the inhibitory effect towards HEWL fibrillation was stronger than that exerted by the previously characterized fibril-forming inhibitor quercetin, which has high structural similarity with myricetin. Spectrofluorometric and computational studies suggest that the mechanism underlying the inhibitory action of myricetin at a molecular level is to reduce the population of partially unfolded HEWL intermediates. This action is achieved by the tight binding of myricetin to the aggregation prone region of the β-domain of HEWL and linking to the relatively stable α-domain, thus, resulting in the inhibition of amyloid fibril formation.
    Journal of Agricultural and Food Chemistry 09/2014; · 3.11 Impact Factor

Full-text (3 Sources)

Download
187 Downloads
Available from
Jun 3, 2014